News - Heptares Therapeutics


Current filters:

Heptares Therapeutics

Popular Filters

Heptares appoints former GSK research head Tim Tasker as CMO

Heptares appoints former GSK research head Tim Tasker as CMO


UK-based drug company Heptares Therapeutics has appointed Tim Tasker as chief medical officer and vice…

BoardroomHeptares TherapeuticsPharmaceuticalUK

Heptares gets first research milestone from Cubist


UK GPCR drug discovery and development company Heptares Therapeutics says it has achieved the first research…

Cubist PharmaceuticalsFinancialHeptares TherapeuticsPharmaceuticalResearch

Oxford BioThera and Boehringer Ingelheim collaborate; Milestone for Heptares


The UK's Oxford BioTherapeutics (OBT) and family-owned German drug major Boehringer Ingelheim have entered…

Boehringer IngelheimHeptares TherapeuticsLicensingNeurologicalOncologyOxford BioTherapeuticsPharmaceuticalResearchTakeda Pharmaceuticals

MorphoSys and Heptares collaborate to develop antibody therapeutics targeting GPCRs


German biotech firm MorphoSys (FSE: MOR) and closely-held UK-based GPCR drug discovery company Heptares…

BiotechnologyHeptares TherapeuticsMorphoSysResearch

Cubist partners with Heptares on new medicines targeting GPCRs; provides 2012 business update


UK-based Heptares Therapeutics, the leading GPCR drug discovery and development company, has signed an…

ceftolozaneCubist PharmaceuticalsFinancialGenito-urinaryHeptares TherapeuticsLicensingPharmaceuticalResearchtazobactam

Shire signs $190 million deal for preclinical CNS drug


Ireland-headquartered drugmaker Shire (LSE: SHP) has exercised its exclusive option to license a novel…

Heptares TherapeuticsLicensingNeurologicalPharmaceuticalShire

Back to top